Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1380, 2011-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In June 2012, the EMA's CHMP recommended that the marketing authorisation granted to Loraxin [loratadine] in Finland should not be recognised

Reactions Weekly, Vol. 1, Iss. 1426, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Epinephrine has been confirmed as the drug of choice for anaphylaxis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 564, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Response to Rituximab: Has the Original Hypothesis Been Confirmed?

Current Pharmaceutical Design, Vol. 21, Iss. 2, 2015-01 ,pp. : 212-220

Bentham Science Publishers

Access to resources Recommend Favorite

Safety updates from EMA's CHMP

Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Health Canada has announced the withdrawal of marketing authorisation for Prexige [lumiracoxib]

Reactions Weekly, Vol. 1, Iss. 1173, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite